23 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
2
Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo.
East China Normal University
19
Facilitating the development of molecular glues: Opportunities from serendipity and rational design.
Sichuan University
20
Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6
The Institute of Cancer Research
13
B-cell Lymphoma 6 Inhibitors: Current Advances and Prospects of Drug Development for Diffuse Large B-cell Lymphomas.
East China Normal University
24
Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors.
The Institute of Cancer Research
4
Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface.
Dana-Farber Cancer Institute
35
Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of
East China Normal University and Shanghai Fengxian District Central Hospital Joint Center For Translational Medicine
16
Free Ligand 1D NMR Conformational Signatures To Enhance Structure Based Drug Design of a Mcl-1 Inhibitor (AZD5991) and Other Synthetic Macrocycles.
AstraZeneca
43
Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
University of Maryland
1
A genetically selected cyclic peptide inhibitor of BCL6 homodimerization.
University of Southampton
14
Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design.
University of Maryland
12
Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach.
Takeda Pharmaceutical
5
Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design.
Takeda Pharmaceutical
7
X-ray Structures of Target-Ligand Complexes Containing Compounds with Assay Interference Potential.
Rheinische Friedrich-Wilhelms-Universit£T
18
Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.
AstraZeneca
5
AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES
Vesper Bio
32
Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
Rugen Holdings (Cayman)